125 related articles for article (PubMed ID: 32580907)
1. p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.
Fabi A; Mottolese M; Di Benedetto A; Sperati F; Ercolani C; Buglioni S; Nisticò C; Ferretti G; Vici P; Perracchio L; Malaguti P; Russillo M; Botti C; Pescarmona E; Cognetti F; Terrenato I
Clin Breast Cancer; 2020 Dec; 20(6):e761-e770. PubMed ID: 32580907
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
3. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Novelli F; Milella M; Melucci E; Di Benedetto A; Sperduti I; Perrone-Donnorso R; Perracchio L; Venturo I; Nisticò C; Fabi A; Buglioni S; Natali PG; Mottolese M
Breast Cancer Res; 2008; 10(5):R74. PubMed ID: 18771580
[TBL] [Abstract][Full Text] [Related]
4. CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients.
Kimbung S; Inasu M; Stålhammar T; Nodin B; Elebro K; Tryggvadottir H; Ygland Rödström M; Jirström K; Isaksson K; Jernström H; Borgquist S
Breast Cancer Res; 2020 Nov; 22(1):123. PubMed ID: 33176848
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
6. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
[TBL] [Abstract][Full Text] [Related]
7. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
8. Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.
Hu J; Fung MW; Tsang JY; Poon IK; Chan SK; Cheung SY; Hu H; Zhou D; Tse GM
Clin Breast Cancer; 2020 Jun; 20(3):253-261.e7. PubMed ID: 32205037
[TBL] [Abstract][Full Text] [Related]
9. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
11. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.
Guarneri V; Barbieri E; Piacentini F; Giovannelli S; Ficarra G; Frassoldati A; Maiorana A; D'Amico R; Conte P
Int J Biol Markers; 2010; 25(2):104-11. PubMed ID: 20544688
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
[TBL] [Abstract][Full Text] [Related]
15. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Malamou-Mitsi V; Gogas H; Dafni U; Bourli A; Fillipidis T; Sotiropoulou M; Vlachodimitropoulos D; Papadopoulos S; Tzaida O; Kafiri G; Kyriakou V; Markaki S; Papaspyrou I; Karagianni E; Pavlakis K; Toliou T; Scopa C; Papakostas P; Bafaloukos D; Christodoulou C; Fountzilas G
Ann Oncol; 2006 Oct; 17(10):1504-11. PubMed ID: 16968874
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
Choi DH; Kim S; Rimm DL; Carter D; Haffty BG
Cancer J; 2005; 11(5):404-11. PubMed ID: 16259871
[TBL] [Abstract][Full Text] [Related]
18. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
19. High casein kinase 1 epsilon levels are correlated with better prognosis in subsets of patients with breast cancer.
Lopez-Guerra JL; Verdugo-Sivianes EM; Otero-Albiol D; Vieites B; Ortiz-Gordillo MJ; De León JM; Praena-Fernandez JM; Marin JJ; Carnero A
Oncotarget; 2015 Oct; 6(30):30343-56. PubMed ID: 26327509
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
Beenken SW; Grizzle WE; Crowe DR; Conner MG; Weiss HL; Sellers MT; Krontiras H; Urist MM; Bland KI
Ann Surg; 2001 May; 233(5):630-8. PubMed ID: 11323501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
